SERACH RESULTS FOR" Development "
development, the demand for CDMOs is steadily increasing. This need for additional capacity is not only reflected in our Plant 4 pre-sales activity, but is also driving us to closely review the investment and construction of a second bio-campus in Songdo, Incheon. 3-Dimensional Expansion : Capacity / Geography / Portfolio Earlier this yera, we shared our '3-Dimensional Expansion' strategy to becoming a fully integrated global top-tier biopharmaceutical company, and I am proud to confirm we are keeping that promise even at this moment. In addition, Samsung Biologics will be proactive in fulfilling our commitment and responsibility to a better planet and social environment as signaled by the issuance of our first annual sustainability report during this past quarter. We will also continue to stay ahead of and respond to evolving market dynamics and client needs to maximize corporate and shareholder value. Thank you for your continued support. Sincerely, John Rim President and CEO, Samsung Biologics
development and manufacturing services according to our strict COVID-19 controls and management systems. Our supply chain management war room monitored and managed availability of critical materials around the clock, while our preemptive development of our Live Virtual Tour platform ensured our ability ot perform client due diligence and regulatory inspections amid worldwide travel restrictions, enabling us to sign additional CMO contracts for a total of 47 cumulative by the end of 2020. Our achievements in 2020 not only demonstrated innovation in the CDMO market but also strengthened our business competitiveness despite the COVID-19 pandemic. Samsung Biologics, I ask for your continued warm attention and support. Sincerely, also established a stable growth foundation by securing full contracts in Plants 1, 2, John Rim President and CEO, Samsung Biologicsand near-full contracts in plant 3. We also made a decisive investment to expand Plant 4 to respond to the accelerated supply/demand situation within the industry. Plant 4 will be the word's most productive facility, with a total of 256,000L, which is 76,000L larger than plant 3. in the CDO (contract Development) business, we successfully launched our proprietary cell line, "S-CHOice" in August. In october, we announced the opening of our R&D center in San Francisco, US. We will continue to evaluate expanding DP (fill finish) facilities to ensure client satisfaction by providing competitive end-to-end services. 2021 - The beginning of a new decade for Samsung Biologics, I ask for your continued warm attention and support. Sincerely, John Rim President and CEO, Samsung Biologics As announced at this year's JP Mogan conference, we are planning to expand our business in 3 aspects : capacity expansion, geography expansion, and scope expansion over the next 10 years: Capacity Expansion By acquiring Bio-campus Ⅱ and plant 4 expansion in Songdo play as game changer beyond CDMO champion Geography Expansion Expansion of CMO and CDO capacity oustide of Korea to maximize customer satisfaction and expand prospects. Scope Expansion Study from mAb based biologics to new potential growth momentum(eg. Cell/gene therapy, vaccine etc.) For the Next Decade 3-Dimensional Expansion - Business Expansion & Portfolio Diversification Source : JP Morgan Healthcare Conference 2021 Samsung Biologics will always advance forward and deliver on ever challenging goals as a CDMO Champion. As we celebrate our 10 year anniversary this year, we will not be complacent with our achievements, but instead commit ourselves even more to continuously innovating our process for superior client satisfaction. Through this, we will strive to increase both customer value while maximizing shareholder value. And we will continue to actively communicate with investors to inform on our business performance. In this new decade of Samsung Biologics, I ask for your continued warm attention and support. Sincerely, John Rim President and CEO, Samsung Biologics
development, to clinical and commercial manufacturing, offering fully integrated, one-stop services. for additional information regarding Plant 4, please visit our newly opened "Plant 4 Virtual Showroom", where you can also track its ongoing construction progress. Bio CMO/CDO/CRO Champing 2030 As a CDMO service provider, Samsung Biologics attained the largest total capacity within the shortest amount of time while ensuring top-notch quality services. We will continue to strengthen our competitive edge through technological innovation and new business development. We will also strive to ensure maximum client satisfaction, optimize shareholder value, and most importantly advance the industry in improving assessibility to healthcare and quality of life. We ask for your continued encouragement and support in buliding a better future with Samsung Biologics. Thank you, Tae Han Kim President & CEO, Samsung Biologics December 3rd, 2020
It’s in our DNA At Samsung Biologics, we continue to demonstrate our operational excellence across all value chains thanks to the unique business DNA our employees share at the company. At our recent branding film we reinforced our shared mission to be ‘Driven. For Life.’ Driven. to take on challenges
To accelerate time to market and meet urgent patient needs, we leverage all available resources in our end-to-end service, while balancing speed and quality. In this whitepaper, Daniel Buckley, our Lead Scientist in CDO Downstream, details how our proprietary technology platform, S-Cellerate™, offers an expedited CDMO timeline to IND. Using S-Cellerate™, clients have been able to reach IND filing in as fast as 9 months as well as access our full spectrum of services - from process characterization and validation to BLA submission - while maintaining the highest product quality and operational robustness.
파일 다운로드를 위해 뉴스레터 구독용 이메일 주소를 입력해주세요.
* 구독자라면 구독중인 이메일 주소를 입력해주세요.
뉴스레터 구독 서비스를 등록하시면 당사 뉴스룸에서 제공되는
삼성바이오로직스의 최신 소식과 관심 분야별 유용한 정보를 받아 보실 수 있습니다.
Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.
Samsung Biologics Confirms 'No Impact' of COVID-19 with Business Continuity Plan in EffectFebruary 25, 2020
-Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Target Anticancer Drugmore
-Naming Biopharmaceutical Products 1 Monoclonal Antibody Drugsmore
-Naming Biopharmaceutical Products 1 Monoclonal Antibody Drugsmore
-Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Target Agreement for Novel Targetmore
-Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Targetmore